|
|
|
|
| LEADER |
03822nma a2200781 u 4500 |
| 001 |
EB002041597 |
| 003 |
EBX01000000000000001185263 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
220822 ||| eng |
| 020 |
|
|
|a 9783036530642
|
| 020 |
|
|
|a books978-3-0365-3065-9
|
| 020 |
|
|
|a 9783036530659
|
| 100 |
1 |
|
|a Bortolotti, Massimo
|
| 245 |
0 |
0 |
|a Toxin and Immunotoxin Based Therapeutic Approaches
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2022
|
| 300 |
|
|
|a 1 electronic resource (122 p.)
|
| 653 |
|
|
|a sugar specificity
|
| 653 |
|
|
|a pokeweed antiviral protein
|
| 653 |
|
|
|a epidermal growth factor
|
| 653 |
|
|
|a plant toxin
|
| 653 |
|
|
|a hepatocellular carcinoma
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a Humanities / bicssc
|
| 653 |
|
|
|a Social interaction / bicssc
|
| 653 |
|
|
|a antibody drug conjugate
|
| 653 |
|
|
|a humanized YP7
|
| 653 |
|
|
|a Pseudomonas Exotoxin A
|
| 653 |
|
|
|a epidermal growth factor receptor
|
| 653 |
|
|
|a patient-derived glioblastoma cell lines
|
| 653 |
|
|
|a Glypican-3
|
| 653 |
|
|
|a stenodactylin
|
| 653 |
|
|
|a primary sequence
|
| 653 |
|
|
|a 3D structure
|
| 653 |
|
|
|a SARS-CoV-2
|
| 653 |
|
|
|a COVID-19
|
| 653 |
|
|
|a kirkiin
|
| 653 |
|
|
|a antiviral agent
|
| 653 |
|
|
|a prostate cancer
|
| 653 |
|
|
|a immunotoxin
|
| 653 |
|
|
|a new recombinant immunotoxin
|
| 653 |
|
|
|a ribosome-inactivating protein
|
| 653 |
|
|
|a immunoliposome
|
| 653 |
|
|
|a targeted toxins
|
| 653 |
|
|
|a cancer therapy
|
| 653 |
|
|
|a quinoin
|
| 653 |
|
|
|a toxic lectin
|
| 653 |
|
|
|a DT3C
|
| 653 |
|
|
|a Chenopodium quinoa wild
|
| 653 |
|
|
|a temozolomide
|
| 653 |
|
|
|a fusion proteins
|
| 653 |
|
|
|a ribosome-inactivating proteins
|
| 653 |
|
|
|a diphtheria toxin
|
| 653 |
|
|
|a drug delivery
|
| 653 |
|
|
|a ricin
|
| 653 |
|
|
|a monoclonal antibody
|
| 700 |
1 |
|
|a Polito, Letizia
|
| 700 |
1 |
|
|a Bolognesi, Andrea
|
| 700 |
1 |
|
|a Bortolotti, Massimo
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-0365-3065-9
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/78835
|z DOAB: description of the publication
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/4929
|7 0
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 580
|
| 082 |
0 |
|
|a 140
|
| 520 |
|
|
|a In 1900, Paul Ehrlich, who was studying ricin and abrin at the time, discovered antibodies and paved the way for immunotherapy. After 120 years, Ehrlich's insight into the therapeutic potential of immunotargeting is still a source of inspiration for many scientists. One of the most studied antibody-based targeting strategies is the carrying of powerful toxins. The generated molecules are immunotoxins, i.e., chimeric proteins obtained by coupling bacterial or plant toxins and antibodies through chemical linking or genetic engineering. Immunotoxins are functionally designed to eliminate the cells responsible for pathological conditions, and they find applications in several fields, ranging from cancer to immunological diseases or pain control. Despite the lack of specificity, even native toxins find clinical application, but the use of unconjugated toxins is limited to loco-regional treatments. A fundamental requirement for the medical application of toxins and their immunoconjugates is in-depth knowledge of their interaction with target cells in terms of binding, uptake, intracellular routing, and substrate specificity. This Special Issue focuses on toxins and immunotoxins that have clinical potential. We hope to give the reader a comprehensive overview of new toxin delivery strategies and toxin-based experimental disease models, both in vitro and in vivo.
|